• Schott Pharma published an August 2026 business factsheet covering FY 2025 results.
• Revenue EUR 986 million; EBITDA EUR 280 million; EBITDA margin 28.4%.
• Global footprint spans 17 production facilities, including four joint ventures, across 15 countries.
• R&D portfolio includes more than 1,300 filed IP rights; 125 R&D employees.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schott Pharma AG & Co. KGaA published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.